TacticScaleWhat Pediatrix Medical Does & How It Makes Money (MD)
Updated October 2026 · reflects Pediatrix Medical's latest reported financials
U.S. physician group specializing in newborn, maternal-fetal, and pediatric care. It earns revenue from the clinical services its affiliated physicians, nurse practitioners, and other clinicians provide inside hospitals and in offices.
How Pediatrix Medical makes money
It earns revenue from the clinical services its affiliated physicians, nurse practitioners, and other clinicians provide inside hospitals and in offices. Much of this work is done in hospital units such as NICUs, labor and delivery, nurseries, and pediatric departments.
What Pediatrix Medical does
Pediatrix Medical Group, formerly MEDNAX, is a U.S. healthcare services company based in Sunrise, Florida, and founded in 1979. Its core business is neonatal care: through a network of affiliated neonatologists, neonatal nurse practitioners, and other pediatric clinicians, it treats premature and medically complex newborns, mostly in hospital NICUs. The company also offers maternal-fetal medicine, meaning inpatient and office-based care for expectant mothers and unborn babies. This care comes from subspecialists, obstetricians, nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. Other services include pediatric intensive care, hospitalist, and surgical services, support for hospital pediatric ERs, labor and delivery, and nurseries, and a newborn hearing screening program. The company took the Pediatrix name in July 2022.
Products & services
- Neonatal intensive care (NICU) physician services
- Maternal-fetal medicine and high-risk obstetric care
- Pediatric intensivist, hospitalist, and surgical services
- Pediatric emergency room, nursery, and labor and delivery support services
- Newborn hearing screening program
What is Pediatrix Medical worth?
On an owner-earnings DCF, Pediatrix Medical's most-likely value is about $57 versus a recent price near $27 (113% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$39) with a margin of safety — so the honest verdict here is “Deeply discounted.” Fair value earns its keep only at the extremes, not in the wide middle.
On the financials alone, $27 is below even the no-growth floor ($39); the market's discount — expectations and sentiment beyond the numbers — is pricing in ≈ -4.0%/yr. A bargain only if that pessimism is overdone.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
OrthoPediatrics (KIDS) · Privia Health (PRVA) · Progyny (PGNY) · PTC Therapeutics (PTCT) · Medpace (MEDP)